ARA-290 vs GHK
Side-by-side comparison of key properties, dosing, and research.
- Summary
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- GHK is the natural tripeptide (Gly-His-Lys) released from human albumin that activates tissue remodeling, collagen synthesis, and anti-aging gene expression. The copper-free form is the biological signaling molecule; it chelates copper in tissue to form GHK-Cu but also has independent biological activity.
- Half-Life
- ~2–4 hours (SC administration)
- Extremely short as free peptide; tissue binding extends local effects
- Admin Route
- SubQ
- SubQ, Topical, Oral
- Research
- —
- —
- Typical Dose
- 4 mg (fixed dose)
- 100–500 mcg
- Frequency
- Once daily
- Daily or 5x per week
- Key Benefits
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Stimulates collagen and extracellular matrix synthesis
- Activates tissue repair gene expression programs
- Anti-aging: reverses 57% of age-related gene changes
- Antioxidant and anti-inflammatory
- Wound healing and skin barrier repair
- Improves skin laxity, texture, and radiance
- Neuroprotective (stimulates NGF, BDNF)
- Anti-fibrotic in liver and lung models
- Side Effects
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Excellent safety profile (naturally occurring peptide)
- Rare: mild injection site reaction (SC)
- No significant adverse effects identified in research
- Stacks With
- —
- —